Rezera

[Rezera @RezeraInc]

Results from RESOLVE-1, our Phase 2 trial of oral #NLRP3 inhibitor ruvonoflast, will be presented at the American Heart Association Scientific Sessions in Chicago.

Javed Butler, MD, presents Saturday, November 7, in a Featured Science session.

https://t.co/Ce3lBNHOf3

#AHA2026

[Rezera @RezeraInc]

A majority of patients with #PeripheralArteryDisease (PAD) carry elevated residual inflammatory risk, even on medication. Later-stage PAD patients can have up to a four-fold increase in cardiovascular death.

https://t.co/cckg8JpA45

#PADAwarenessMonth

[Rezera @RezeraInc]

We are excited to announce the upcoming launch of our REVEAL-PAD study to investigate the role of inflammation in #PAD and to identify patients who may be eligible for our planned Phase 3 trial of ruvonoflast in PAD.

Read the full press release: https://t.co/UQ5LHbvpj7

[Rezera @RezeraInc]

Why target #inflammation upstream in #PeripheralArteryDisease?

Blocking a downstream signal addresses one branch, but #NLRP3 targets the point where the signal is generated.

Learn more: https://t.co/Y1OgSLeDLc

#PADAwarenessMonth #DrugDevelopment

[Rezera @RezeraInc]

#DYK 230 million people worldwide suffer from #PeripheralArteryDisease, a form of atherosclerotic #CardiovascularDisease?

September is #PADAwarenessMonth, and we will be posting throughout the month promoting awareness of PAD.

[Rezera @RezeraInc]

We are thrilled to report positive topline results from RESOLVE-1, our Phase 2 trial of ruvonoflast.

Ruvonoflast met the primary inflammation endpoint, with a statistically meaningful reduction in hsCRP at week 24 versus placebo.

https://t.co/Y1OgSLeDLc

#ClinicalTrials

[Rezera @RezeraInc]

Today, NodThera becomes Rezera.

Rezera's primary focus is the clinical progression of ruvonoflast into a registrational Phase 3 study in #PeripheralArteryDisease (PAD), the first time an NLRP3 inhibitor is being evaluated in Phase 3.

Learn more: https://t.co/RRyXywAK9P

[Rezera @RezeraInc]

@NodThera will participate in the Cantor Global Healthcare Conference being held September 9-11, 2026, in New York, NY.
https://t.co/Y1Z0gaJlXn

[Rezera @RezeraInc]

Thank you to Peter Libby and Michael Honigberg for the excellent editorial on our recent publication in @JACCJournals.

Link to our paper (open access) here: https://t.co/HsCPQgUgfL

Link to the editorial: https://t.co/hwzwQ0qbU0

[Rezera @RezeraInc]

Presented today at #EASCongress2026 and concurrently published in @JACC Journals: ruvonoflast showed a robust and sustained 82% reduction in hsCRP together with improvements in cardiometabolic biomarkers.

PR: https://t.co/PhZzGyZNVo

Publication: https://t.co/HsCPQgUgfL

[Rezera @RezeraInc]

Our late-breaking EAS 2026 presentation is now available on our website. Learn more about the Phase 1b #ruvonoflast data, including an 82% reduction in hsCRP: https://t.co/qr2lHcai8E

#ASCVD #NLRP3

[Cardiology Today @CardiologyToday]

Ruvonoflast reduced high-sensitivity C-reactive protein and other inflammatory biomarkers at 28 days vs. placebo in certain patients with elevated hsCRP at high CV risk.
#EASCongress 2026 @EASCongress @society_eas @JACCJournals @NodThera
https://t.co/dKKpeqj2cZ

[Rezera @RezeraInc]

@CardiologyToday @EASCongress @society_eas @JACCJournals Thank you for highlighting our work!

[Rezera @RezeraInc]

Our CMO, @drjtgeorge, will join leaders across biotech and healthcare to discuss innovation in cardiometabolic disease and inflammation-driven therapies at the 2nd Annual Obesity & Cardiometabolic Innovation Forum (#Sachs_OCIF) on June 5, ahead of #ADA2026.

[JACC Journals @JACCJournals]

Ruvonoflast, an oral NLRP3 inhibitor, provides early, sustained, & reversible reductions in #hsCRP & significantly lowers inflammatory biomarkers IL-6 & fibrinogen in cardiometabolic patients with elevated #ASCVD risk https://t.co/HAQsOzox8i

#EASCongress2026 #JACC @ProfKausikRay

[Rezera @RezeraInc]

Presented today at #EASCongress2026 and concurrently published in @JACC Journals: ruvonoflast showed a robust and sustained 82% reduction in hsCRP together with improvements in cardiometabolic biomarkers.

PR: https://t.co/PhZzGyZNVo

Publication: https://t.co/HsCPQgUgfL

[Rezera @RezeraInc]

Chronic #inflammation is a key driver of ASCVD, even when LDL-C is controlled.

At @NodThera, #ruvonoflast showed sustained reductions in inflammatory biomarkers linked to cardiovascular risk.

Ahead of #EASCongress2026 @society_eas, we’re sharing perspectives from @ProfKausikRay

[Rezera @RezeraInc]

NodThera will present late‑breaking data at #EASCongress2026 in Athens.

@profkausikray will share clinical findings on #ruvonoflast, our lead oral #NLRP3 inhibitor, joined by CMO @drjtgeorge.

Meet us May 26.

https://t.co/Kfe03HdICt

[Rezera @RezeraInc]

NodThera will be participating in three investor conferences in April.
Learn more at https://t.co/0iMsythxf3

[Rezera @RezeraInc]

@NodThera will be participating in the upcoming @KeystoneSymp: Immunometabolism in Cardiometabolic Disease and Obesity, taking place March 22–25.

Our CSO, Alan Watt will present our perspective on #NLRP3 Inhibitors for the Treatment of Cardiometabolic Disease and Obesity.

[Rezera @RezeraInc]

We are looking forward to join the biotech community at #BIOEuropeSpring in Lisbon.

If you’ll be attending, we would welcome the opportunity to connect and discuss how targeting #NLRP3-driven inflammation could open new therapeutic possibilities.